Skip to content

Deep Learning Model and Risk Factors for Tacrolimus-related Acute Kidney Injury

Research on the Risk Warning Model and Prevention Strategies for Acute Kidney Injury Associated With Tacrolimus Based on Explainable Deep Neural Networks and Therapeutic Drug Monitoring

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06596798
Enrollment
1200
Registered
2024-09-19
Start date
2024-09-01
Completion date
2026-12-30
Last updated
2024-09-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

AKI

Keywords

Acute kidney injury, Therapeutic Drug Monitoring, deep learning

Brief summary

In this study, the investigators aim to develop a risk prediction model for acute kidney injury (AKI) in hospitalized patients using the calcineurin inhibitor tacrolimus. This will be achieved by mining electronic medical record data and employing explainable deep learning methods. The model will provide clinical decision support for timely intervention and treatment. Compared to traditional machine learning models, deep neural networks can extract more nuanced features from complex medical data and perform more precise pattern recognition, thereby enhancing prediction accuracy and reliability. By constructing a predictive tool based on explainable deep learning models, the investigators will better assess the association between the use of calcineurin inhibitors and AKI, explore targeted prevention strategies, and offer more precise predictions and intervention guidance to clinicians. Additionally, this research has significant socio-economic benefits and application potential. By reducing the incidence of AKI, the investigators can lower patient hospitalization duration and re-treatment costs, conserve medical resources, and improve patient quality of life. Preventive healthcare not only alleviates the physical and psychological burden on patients but also reduces the strain on the healthcare system, enhances healthcare efficiency, and promotes the rational allocation of medical resources.

Interventions

None listed

Sponsors

Qianfoshan Hospital
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Use of tacrolimus during hospitalization, with standardized therapeutic drug monitoring * Age of 18 years or older at the time of admission * Length of hospital stay ≥ hours * At least two serum creatinine level tests conducted during the hospital stay

Exclusion criteria

* Stage 5 chronic kidney disease prior to admission * Incomplete clinical data * Serum creatinine levels consistently below 40 mmol/L during hospitalization

Design outcomes

Primary

MeasureTime frameDescription
AKIFrom January 2020 to December 2023Acute kidney injury occurred after the patient took tacrolimus during hospitalization

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026